Melanoma Medical Services in China

Melanoma is a malignant neoplasm arising from melanocytes—pigment-producing cells predominantly located in the epidermis, but also found in mucosal surfaces, uveal tract, and meninges. It accounts for the majority of skin cancer–related mortality despite representing only ~1% of all skin cancers. Key risk factors include ultraviolet radiation exposure, fair skin phenotype, numerous atypical nevi, and genetic predispositions such as CDKN2A mutations. Clinical presentation ranges from asymmetrical, irregularly pigmented lesions (ABCDE criteria) to amelanotic variants, with staging guided by Breslow thickness, ulceration status, mitotic rate, and nodal or distant metastasis (AJCC 8th edition). Management hinges on early surgical excision with appropriate margins; advanced cases may require sentinel lymph node biopsy, adjuvant immunotherapy (e.g., anti-PD-1 agents like pembrolizumab), targeted therapy (BRAF/MEK inhibitors for BRAF V600-mutated tumors), or radiotherapy. Prognosis correlates strongly with stage at diagnosis—5-year survival exceeds 99% for localized disease but drops to <30% in stage IV with visceral involvement.

China offers compelling advantages for melanoma care: Tier-1 oncology centers—including Peking University Cancer Hospital, Fudan University Shanghai Cancer Center, and Sun Yat-sen University Cancer Center—host multidisciplinary melanoma tumor boards staffed by nationally recognized dermatologic oncologists, surgical oncologists, and molecular pathologists. These institutions utilize next-generation sequencing for comprehensive genomic profiling, digital dermoscopy with AI-assisted lesion analysis, and PET-CT/MRI fusion imaging for precise staging. Over 85% of stage III patients treated with combined immunotherapy regimens achieve progression-free survival beyond 24 months—comparable to U.S./EU benchmarks—while average treatment costs remain 40–60% lower than in Western countries, without compromising evidence-based protocols or regulatory compliance (NMPA-approved biologics and small molecules). As a dedicated medical tourism agency, we facilitate seamless international patient journeys: verifying physician credentials, coordinating appointments across specialized departments, providing itemized, pre-authorized cost estimates, arranging visa support and local logistics, and assigning bilingual clinical liaisons for continuity of care—from initial consultation through follow-up.

Medical Travel to China Guide: Melanoma (Oncology)

Patients traveling to China for melanoma treatment must obtain a Medical Visa (Q2 or S2), requiring an invitation letter from the treating hospital and proof of diagnosis. We assist with visa documentation, appointment scheduling, and translation support throughout the process. Regarding medical insurance, most international policies do not cover treatment in China; however, we provide transparent, itemized cost estimates upfront—including consultations, genomic testing, immunotherapy (e.g., anti-PD-1), surgery, and follow-up—and facilitate secure payments via bank transfer or credit card. Our team coordinates accommodation near partner hospitals (e.g., Peking Union Medical College Hospital or Fudan University Shanghai Cancer Center), offering options from serviced apartments to premium hotels, plus companion visas and local transport. Post-treatment, our dedicated oncology coordinators schedule virtual check-ins every 2–4 weeks for 6 months, review pathology reports, liaise with your home physician, and arrange remote consultations with Chinese specialists. All services—including translation, logistics, and care coordination—are included in our fixed-service fee, ensuring clarity and continuity from arrival through recovery.